Cover Image

In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters

Cancer vaccines provide a complex source of neoantigens. Still, increasing evidence reveals that the neoantigen quality rather than the quantity is predictive for treatment outcome.

Saved in:
Bibliographic Details
Main Authors: Salewski, Inken (Author) , Gladbach, Yvonne S. (Author) , Kuntoff, Steffen (Author) , Irmscher, Nina (Author) , Hahn, Olga (Author) , Junghanß, Christian (Author) , Maletzki, Claudia (Author)
Format: Article (Journal)
Language:English
Published: 21 October 2020
In: Journal of translational medicine
Year: 2020, Volume: 18, Pages: 1-15
ISSN:1479-5876
DOI:10.1186/s12967-020-02570-y
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12967-020-02570-y
Get full text
Author Notes:Inken Salewski, Yvonne Saara Gladbach, Steffen Kuntoff, Nina Irmscher, Olga Hahn, Christian Junghanss and Claudia Maletzki
Description
Summary:Cancer vaccines provide a complex source of neoantigens. Still, increasing evidence reveals that the neoantigen quality rather than the quantity is predictive for treatment outcome.
Item Description:Gesehen am 30.11.2020
Physical Description:Online Resource
ISSN:1479-5876
DOI:10.1186/s12967-020-02570-y

Similar Items